Giordano and Columbano, 2014) was the first drug for first-line treatment of advanced HCC (Marisi et al., 2019
The study adopts a case study approach, incorporating field research that includes interviews with key informants, direct observations, and household surveys
Published studies document these effects in gut inflammatory models and skin wound models
BPC-157 is not FDA-approved for therapeutic use and should be considered investigational
Clinical Evidence Human clinical studies provide compelling support for topical ghk cu efficacy: A 12-week thigh skin application study demonstrated improved collagen production in 70% of women versus 50% with vitamin C A pilot study by Krger et al
In March 2024, Wegovy was also approved to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular (heart, blood vessel) disease and either obesity or overweight